Boston Scientific Corporation (BSX) Gets CE Mark Approval For SYNERGY Stent
10/31/2012 10:33:30 AM
Boston Scientific Corp. (BSX: Quote) said it received CE Mark approval for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating.
The SYNERGY Stent is the latest innovation in drug-eluting stent technologyfrom Boston Scientific. It is unique in that its proprietary PLGA polymer and everolimus drug coating dissipate by three months. This innovation has the potential to improve post-implant vessel healing and will eliminate long-term polymer exposure, a possible cause of late adverse events.